Alnylam Pharmaceuticals News

BUYINS.NET / www.squeezetrigger.com is monitoring ALNYLAM PHARMACEU in real time and just received an alert that is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock.

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the Piper Jaffray 21 st Annual Health Care Conference on Wednesday, December 2, 2009, at 8:00 a.m. ET at The New York Palace Hotel.

An American biotech company is planning to use a new technique called RNA interference to boost yields of biological drugs by improving the performance of drug-producing cell cultures.

Biotech firm hopes to use RNA interference to boost drug yields. Chinese hamster ovary cells: the workhorse of the biological drug market.

Nov 18, 2009 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced new pre-clinical data from its ALN-VSP program presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International conference being held November 15 - 19, 2009 in Boston, Mass.

Alnylam is developing RNAi therapeutics for the treatment of both RSV infection and ATTR, amongst other pipeline programs.

Alnylam Pharmaceuticals Inc. reported a third-quarter loss of 22 cents per share, below the Zacks Consensus Estimate of 24 cents but wider than the year-ago loss of 7 cents.

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will webcast its upcoming R&D Day live on the "Investors" section of the company's website at www.alnylam.com . Alnylam scientists and management will review and provide updates on Alnylam platform advancements, delivery strategies, and pipeline of novel ...

Nov 5, 2009 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that it presented new data related to its overall delivery research efforts including the rational design of Mimetic Lipoprotein Particles, or MLPs, a novel technology for the systemic delivery of small interfering RNAs, or siRNAs, the molecules that ...

Drug stocks gained Thursday, but shares of Alnylam Pharmaceuticals fell a day after the company reported a widened third-quarter loss and said its search for research partners is taking longer than expected.

OMAHA, Neb.-- --Fred Tomczyk, president and chief executive officer of TD AMERITRADE Holding Corporation , will give a presentation and Q&A session on Thursday, Nov.

Here It Here First!! Sign Up For Our Free Newsletter!! "Total Nutraceutical Solutions Enters Into Agreement With Model Biosystems to Test Proprietary Mushroom Compounds in Suppressing Alzeheimer's Disease" STOCK MARKETING INC PRESENTS : www.StockMarketingInc.com To sign up for our free Profiles & Alerts :: visit ...

SmarTrend, our proprietary pattern recognition system, called a Downtrend for Alnylam Pharmaceuticals on October 02, 2009 at $21.42. Since then, Alnylam Pharmaceuticals has returned 20.2% as of Friday's recent price of $17.10. Want to profit from these alerts? Go to www.mysmartrend.com now for a FREE two-week trial.

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will report financial results for the third quarter ending September 30, 2009 on Wednesday, November 4, 2009, after the U.S. financial markets close.

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. , and Isis Pharmaceuticals, Inc.

Xconomy.com -- Alnylam Pharmaceuticals had more than $470 million in the bank as of the last official count at the end of June, so it struck me as odd that the Cambridge, MA-based developer of gene-silencing drugs was a presenter along with dozens of cash-starved biotech startups at the MassBio Investors Forum in Boston yesterday.

Ted Torphy, chief scientific officer at Johnson & Johnson, was the moderator at the MassBio Investors Forum at the Sheraton Boston.

Emily Walsh is on to a new adventure. After two years as a program manager at Alnylam Pharmaceuticals, she is striking out on her own to form a new biotechnology firm.